Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
Jean‐Marc Nabholtz(AstraZeneca (United Kingdom)), Mia von Euler(University Hospital of North Norway), William N. Harwin(AstraZeneca (United Kingdom)), Aman U. Buzdar(The University of Texas MD Anderson Cancer Center), Alan Webster(AstraZeneca (United Kingdom)), G. Burton(AstraZeneca (United Kingdom)), Mark L. Steinberg(AstraZeneca (United Kingdom)), A Mangalik(Unknown), Michaël Pollak(McGill University)
Cited by 996
Related Papers
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
|The Lancet|1998|1.8k
Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer Cells
|Cancer Research|2006|1k
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
|Journal of Clinical Oncology|2000|840